TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22301361

Group type: EXPERIMENTAL
Intervention: Open lateral retinacular lengthening
Number of subjects: 28

Group type: COMPARATOR
Intervention: Open lateral retinacular release
Number of subjects: 28
Study: 20813485

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch 130/0.4
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 20
Study: 17544636

Group type: EXPERIMENTAL
Intervention: Outpatient psychotherapy (specific type not mentioned)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Healthcare-related costs
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Total societal costs
Number of subjects: 88
Study: 16170175

Group type: EXPERIMENTAL
Intervention: L-BLP25 plus best supportive care (BSC)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 171
Study: 12431827

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1200 mg/m² on days 1 and 8 plus carboplatin at an area under the curve of 5 mg/ml/min on day 1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gemcitabine 1200 mg/m² on days 1 and 8 plus cisplatin 80 mg/m² on day 1 every 21 days
Number of subjects: 0
Study: 7949831

Group type: EXPERIMENTAL
Intervention: Basal FSH measurements in ovulatory patients
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Basal FSH measurements in anovulatory patients
Number of subjects: 131
Study: 3675403

Group type: EXPERIMENTAL
Intervention: Low pressure suction drain
Number of subjects: 0

Group type: COMPARATOR
Intervention: High pressure suction drain
Number of subjects: 0

Group type: COMPARATOR
Intervention: Passive drain
Number of subjects: 0
Study: 29650207

Group type: EXPERIMENTAL
Intervention: Community-based spiritual life review program
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (received the same program after the study)
Number of subjects: 52
Study: 28872480

Group type: EXPERIMENTAL
Intervention: Norepinephrine (10 µg)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Phenylephrine (137 µg)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Norepinephrine (8 µg)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Norepinephrine and Phenylephrine
Number of subjects: 180
Study: 26165735

Group type: EXPERIMENTAL
Intervention: Suction pseudopolyp technique
Number of subjects: 112

Group type: COMPARATOR
Intervention: Cold snare polypectomy
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 112
Study: 23266540

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg) administered at bedtime
Number of subjects: 21

Group type: COMPARATOR
Intervention: Captopril (not specified dosage)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Healthy controls (no intervention specified)
Number of subjects: 21
Study: 21512499

Group type: EXPERIMENTAL
Intervention: Cytoflavin
Number of subjects: 64
Study: 19361598

Group type: EXPERIMENTAL
Intervention: Aspirin (≤325 mg/day)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Aspirin plus extended-release dipyridamole (ER-DP)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Aspirin plus clopidogrel
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Anticoagulation (warfarin and other vitamin K antagonists)
Number of subjects: 13
Study: 17018383

Group type: EXPERIMENTAL
Intervention: Deferasirox 10 mg/kg/day (modified after 12 weeks)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Deferasirox 10 mg/kg/day (mean dose 11.3 mg/kg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Deferasirox (once-daily dosing)
Number of subjects: 40
Study: 15466880

Group type: EXPERIMENTAL
Intervention: Pamidronate (60 mg at baseline, 30 mg at months 1, 2, 3, and 6)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control (no pamidronate)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Pamidronate
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control
Number of subjects: 57
Study: 10906163

Group type: EXPERIMENTAL
Intervention: ABT-627 (20 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: ABT-627 (5 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 9
Study: 9409566

Group type: EXPERIMENTAL
Intervention: Laparoscopic repair
Number of subjects: 273

Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 273
Study: 8103655

Group type: EXPERIMENTAL
Intervention: Albuterol (200 micrograms)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Broxaterol (400 micrograms)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 3252453

Group type: EXPERIMENTAL
Intervention: CW dye laser treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: CW argon laser treatment
Number of subjects: 20
Study: 29486720

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (200 μg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Intrathecal placebo
Number of subjects: 42
Study: 27914744

Group type: EXPERIMENTAL
Intervention: 4CMenB
Number of subjects: 468

Group type: COMPARATOR
Intervention: Vaccine-naïve controls
Number of subjects: 468
Study: 26183611

Group type: EXPERIMENTAL
Intervention: GS-5816 150 mg for 3 days
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: GS-5816 5-150 mg for 3 days
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: GS-5816 (all doses)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Patients without pretreatment NS5A resistance-associated polymorphisms
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Patients with pretreatment NS5A resistance-associated polymorphisms
Number of subjects: 70
Study: 24645552

Group type: EXPERIMENTAL
Intervention: S-amlodipine
Number of subjects: 127

Group type: COMPARATOR
Intervention: Racemic amlodipine
Number of subjects: 127
Study: 22093927

Group type: EXPERIMENTAL
Intervention: TRAE plus cryoablation (Group B)
Number of subjects: 104

Group type: COMPARATOR
Intervention: TRAE (Group A)
Number of subjects: 104
Study: 19716484

Group type: EXPERIMENTAL
Intervention: Dentaport ZX
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Raypex 5
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Elements Diagnostic Unit and Apex Locator
Number of subjects: 60
Study: 17476010

Group type: EXPERIMENTAL
Intervention: Higher glycated hemoglobin values
Number of subjects: 1144

Group type: COMPARATOR
Intervention: Severe hypoglycemia
Number of subjects: 1144
Study: 15507943

Group type: EXPERIMENTAL
Intervention: 100 mg of meperidine
Number of subjects: 407

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 407
Study: 11675899

Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg orally once daily for 12 weeks
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 123
Study: 9135352

Group type: EXPERIMENTAL
Intervention: Light halothane anaesthesia (1% end-tidal concentration) with propofol (3 mg kg-1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Deep halothane anaesthesia (2% end-tidal concentration)
Number of subjects: 100
Study: 7957980

Group type: EXPERIMENTAL
Intervention: Transdermal E2 patch, 0.1 mg for 25 days each month (n = 7)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Transdermal E2 with MPA, 10 mg from days 16 to 25 each month (n = 7)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Oral equine estrogens, 1.25 mg (n = 8)
Number of subjects: 14
Study: 3621635

Group type: EXPERIMENTAL
Intervention: Verapamil (160-480 mg/day)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Atenolol (50-100 mg/day) plus Hydralazine (50-200 mg/day)
Number of subjects: 16
Study: 30121600

Group type: EXPERIMENTAL
Intervention: Perturbation-based balance training (PBT)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Traditional balance training (control)
Number of subjects: 88
Study: 26451695

Group type: EXPERIMENTAL
Intervention: Free fat grafting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acellular dermis grafting
Number of subjects: 0
Study: 25603750

Group type: EXPERIMENTAL
Intervention: Fascial Manipulation(®) (FM)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Low‐Level Laser Therapy (LLLT)
Number of subjects: 42
Study: 23514286

Group type: EXPERIMENTAL
Intervention: Closure of patent foramen ovale
Number of subjects: 980

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 980
Study: 20978741

Group type: EXPERIMENTAL
Intervention: Low GI fruit intake
Number of subjects: 152

Group type: COMPARATOR
Intervention: High fibre dietary advice
Number of subjects: 152
Study: 18627642

Group type: EXPERIMENTAL
Intervention: 2% dorzolamide/0.5% timolol fixed combination (DTFC)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Timolol
Number of subjects: 232
Study: 16640481

Group type: EXPERIMENTAL
Intervention: VR distraction using Street Luge (5DT), presented via a head‐mounted display
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard of care (topical anesthetic) with no distraction
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: VR distraction using Street Luge (5DT)
Number of subjects: 20
Study: 12594778

Group type: EXPERIMENTAL
Intervention: High pesticide usage (1,3-dichloropropene, captafol, pentachloronitrobenzene, dieldrin)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Non-cancer deaths (control group)
Number of subjects: 102
Study: 10642377

Group type: EXPERIMENTAL
Intervention: Ethanol after exercise (ExEt)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Resistance exercise (Ex)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control
Number of subjects: 9
Study: 8797125

Group type: EXPERIMENTAL
Intervention: Recent vertebral fractures (within the previous 4 years)
Number of subjects: 645

Group type: EXPERIMENTAL
Intervention: Self-reported disk problems
Number of subjects: 645

Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 645

Group type: EXPERIMENTAL
Intervention: Number of other painful joints
Number of subjects: 645

Group type: EXPERIMENTAL
Intervention: Height, spine bone mineral density (BMD), calcaneus BMD, smoking, and number of live births
Number of subjects: 645
Study: 1639879

Group type: EXPERIMENTAL
Intervention: Codeine syrup B.P. (30 mg/10 ml, q.d.s.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Syrup vehicle (placebo)
Number of subjects: 0
Study: 6711556

Group type: EXPERIMENTAL
Intervention: 6 months of maintenance therapy (n = 8)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 15 months of maintenance therapy (n = 13)
Number of subjects: 52
Study: 30836871

Group type: EXPERIMENTAL
Intervention: Higher ratings of gods as monitoring and punishing
Number of subjects: 2228

Group type: EXPERIMENTAL
Intervention: Punishing and monitoring gods
Number of subjects: 2228
Study: 29175714

Group type: EXPERIMENTAL
Intervention: Electrical stimulation to the plantar intrinsic foot muscles (PIFMs) from mid-stance to pre-swing using surface electrodes
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no electrical stimulation)
Number of subjects: 20
Study: 26856909

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-Piperaquine (DHA-PPQ)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 128
Study: 23996287

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 22739977

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 268
Study: 20061026

Group type: EXPERIMENTAL
Intervention: LSA+MPL/TDM/CWS
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: LSA+BCG
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: LSA+AdjuPrime
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 3
Study: 17890316

Group type: EXPERIMENTAL
Intervention: Combined diet-and-exercise intervention
Number of subjects: 147

Group type: COMPARATOR
Intervention: Control program
Number of subjects: 147
Study: 15199092

Group type: EXPERIMENTAL
Intervention: ABVD plus subtotal nodal irradiation (STNI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ABVD plus involved-field radiotherapy (IFRT)
Number of subjects: 0
Study: 11535506

Group type: EXPERIMENTAL
Intervention: PBSC
Number of subjects: 107
Study: 9513099

Group type: EXPERIMENTAL
Intervention: Ivoclar‐Vivodent and Orthotyp
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Dentsply‐Trublend SLM
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Dentsply‐Bioblend IPN
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Individual tooth wear (canine, premolar, molar)
Number of subjects: 67
Study: 8071266

Group type: EXPERIMENTAL
Intervention: Combined treatment (18 sessions of CBT plus desipramine withdrawn at 24 weeks)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral therapy (CBT) alone (18 sessions)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Desipramine (16 weeks)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Desipramine (24 weeks)
Number of subjects: 61
Study: 2920585

Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg every 12 h
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Dexamethasone 1 mg every 12 h
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.25 mg every 12 h
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 1084093

Group type: EXPERIMENTAL
Intervention: Simultaneous vaccination with BCG and measles vaccine
Number of subjects: 1000

Group type: COMPARATOR
Intervention: BCG vaccine alone
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Measles vaccine alone
Number of subjects: 1000
Study: 31812609

Group type: EXPERIMENTAL
Intervention: Sleep Education Program (SEP)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Healthy Living Program (HLP)
Number of subjects: 210
Study: 30606784

Group type: EXPERIMENTAL
Intervention: Zoledronate
Number of subjects: 34

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 34
Study: 28502280

Group type: EXPERIMENTAL
Intervention: Feedback-controlled mandibular positioner (FCMP) test
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Custom oral appliance treatment
Number of subjects: 202
Study: 25279818

Group type: EXPERIMENTAL
Intervention: Noribogaine 3 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Noribogaine 10 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Noribogaine 30 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Noribogaine 60 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 24107875

Group type: EXPERIMENTAL
Intervention: Piascledine (300 mg daily for two months, combined with artrosilene 320 mg daily for the first month)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Artrosilene (NSAIDs, monotherapy)
Number of subjects: 0
Study: 20430409

Group type: EXPERIMENTAL
Intervention: 6 trials of hands‐on practice of the pyloroplasty procedure
Number of subjects: 16

Group type: COMPARATOR
Intervention: No practice (control group)
Number of subjects: 16
Study: 19194327

Group type: EXPERIMENTAL
Intervention: 6-week Math intervention (n = 28)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard psychoeducational contrast group (n = 26)
Number of subjects: 54
Study: 15710002

Group type: EXPERIMENTAL
Intervention: FLCA group (famotidine 20 mg b.d., lansoprazole 30 mg b.d., clarithromycin 200 mg b.d., amoxicillin 750 mg b.d. for 1 week)
Number of subjects: 177

Group type: COMPARATOR
Intervention: LCA group (lansoprazole 30 mg b.d., clarithromycin 200 mg b.d., amoxicillin 750 mg b.d. for 1 week)
Number of subjects: 177
Study: 12000375

Group type: EXPERIMENTAL
Intervention: Histamine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Substance P
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Neurokinin A
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Trypsin
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Platelet-activating factor (PAF)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Serotonin
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Neurokinin B
Number of subjects: 32

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 32
Study: 9706928

Group type: EXPERIMENTAL
Intervention: Intrathecal neostigmine 25 microg
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 100 microg
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Combination of intrathecal neostigmine 12.5 microg and morphine 50 microg
Number of subjects: 79

Group type: COMPARATOR
Intervention: Isotonic sodium chloride solution 0.2 mL
Number of subjects: 79
Study: 7882125

Group type: EXPERIMENTAL
Intervention: Cybex 6000 isokinetic testing device (ITD)
Number of subjects: 59

Group type: COMPARATOR
Intervention: ordinary leg extension bench (LEB)
Number of subjects: 59
Study: 2118925

Group type: EXPERIMENTAL
Intervention: Peripheral parenteral nutrition (PPN) for 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Elemental feedings for 2 weeks
Number of subjects: 0
Study: 717761

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine with adrenaline
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with adrenaline
Number of subjects: 100

Group type: COMPARATOR
Intervention: General anaesthetic (control group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Lignocaine caudal block (control group)
Number of subjects: 100
Study: 27749803

Group type: EXPERIMENTAL
Intervention: Clowns (n = 18)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Dogs (n = 24)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Musicians (n = 15)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (CG) (N = 48)
Number of subjects: 105
Study: 28857595

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) for 3.5 months
Number of subjects: 118

Group type: COMPARATOR
Intervention: Wait-list control group receiving standard medical care for 3.5 months
Number of subjects: 118
Study: 26278470

Group type: EXPERIMENTAL
Intervention: Inference-Based Approach (IBA)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 90
Study: 23575031

Group type: EXPERIMENTAL
Intervention: iQuit system (web-based program and automated tailored text messages)
Number of subjects: 600

Group type: COMPARATOR
Intervention: usual care (Control)
Number of subjects: 600
Study: 21878070

Group type: EXPERIMENTAL
Intervention: Conventional therapy plus ethylmethylhydroxypyridine succinate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 100
Study: 19164318

Group type: EXPERIMENTAL
Intervention: EPO 36 000 IU
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 17313998

Group type: EXPERIMENTAL
Intervention: 50 microg of LT
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 15531626

Group type: EXPERIMENTAL
Intervention: Osteopathy plus usual GP care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual GP care alone
Number of subjects: 0
Study: 11557167

Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Naltrexone 100 mg
Number of subjects: 19

Group type: COMPARATOR
Intervention: Naltrexone 0 mg (Control)
Number of subjects: 19
Study: 9644751

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg daily for 3 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Co-amoxiclav 625 mg 3 times a day for 10 days
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Co-amoxiclav
Number of subjects: 50
Study: 8043072

Group type: EXPERIMENTAL
Intervention: Reduction in serum cholesterol concentration of 0.6 mmol/l (about 10%)
Number of subjects: 500000
Study: 3362276

Group type: EXPERIMENTAL
Intervention: diatrizoate (1,800 mmol/kg H2O)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: ioxaglate (600 mmol/kg H2O)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: iohexol (850 mmol/kg H2O)
Number of subjects: 23
Study: 31950167

Group type: EXPERIMENTAL
Intervention: Experience Corps program (volunteering at elementary schools)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Low-activity control group
Number of subjects: 336
Study: 30337273

Group type: EXPERIMENTAL
Intervention: BVS857 (0.06 mg/kg intravenously once a week for 12 weeks)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: BVS857
Number of subjects: 27

Group type: COMPARATOR
Intervention: BVS857 and Placebo
Number of subjects: 27
Study: 27571927

Group type: EXPERIMENTAL
Intervention: Atezolizumab in combination with bevacizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination treatment (Atezolizumab + Bevacizumab)
Number of subjects: 0
Study: 25677278

Group type: EXPERIMENTAL
Intervention: Educational pamphlets written at a grade 5 reading level
Number of subjects: 179

Group type: COMPARATOR
Intervention: Educational pamphlets written at a grade 10 reading level
Number of subjects: 179
Study: 23272986

Group type: EXPERIMENTAL
Intervention: Mindfulness therapy (mindfulness‐based stress reduction and some cognitive behavioral therapy elements for BDS)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Enhanced treatment as usual (2‐hour specialist medical care and brief cognitive behavioral therapy for BDS)
Number of subjects: 119
Study: 20679587

Group type: EXPERIMENTAL
Intervention: Ketamine hydrochloride (0.5 mg/kg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 19018213

Group type: EXPERIMENTAL
Intervention: Creating Opportunities for Parent Empowerment (COPE)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 246
Study: 16170119

Group type: EXPERIMENTAL
Intervention: Dorzolamide
Number of subjects: 140

Group type: COMPARATOR
Intervention: Timolol
Number of subjects: 140
Study: 11788429

Group type: COMPARATOR
Intervention: Intravenous terbutaline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Drug-free state
Number of subjects: 0
Study: 10027483

Group type: EXPERIMENTAL
Intervention: Zadaxin (SciClone)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Timosina (Sclavo)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Thymosin alpha1 (Tal-HLR; Hoffmann La Roche)
Number of subjects: 9